<DOC>
	<DOCNO>NCT02557633</DOCNO>
	<brief_summary>There increase evidence effectiveness allergy immunotherapy control symptom rhinoconjunctivitis related cumulative dose allergen allergoid administer single regimen subcutaneous ( SC ) injection sublingual administration . Two new cumulative dos Grass MATA MPL 10200 18200 SU ( Standardized Units ) develop compare current dose 5100 SU . The purpose study evaluate tolerability safety two new cumulative dose regimen Grass MATA MPL compare placebo patient seasonal allergic rhinoconjunctivitis ( SAR ) due grass pollen , enable selection best dose go large scale study assess efficacy safety higher cumulative dos .</brief_summary>
	<brief_title>A Study Tolerability Safety Two New Doses Grass MATA MPL</brief_title>
	<detailed_description>Structure : Single center , parallel group , single-blind , randomize study There three treatment group , two group receive different , cumulative dose Grass MATA MPL third group receive placebo . Duration : The duration study screen final visit treatment expect approximately 7 week . There telephone follow 1 , 3 , 6 12 month treatment .</detailed_description>
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Monophosphoryl lipid A</mesh_term>
	<criteria>Patients must positive skin prick test grass pollen allergen . Positive skin prick test positive histamine control Negative skin prick test negative control Specific IgE grass pollen document radioallergosorbent equivalent test class ≥ 2 History least 2 season moderate severe seasonal rhinoconjunctivitis due IgE mediate allergy pollen grass Males nonpregnant , nonlactating female : Postmenopausal ( define least 12 month natural spontaneous amenorrhea least 6 week follow surgical menopause , i.e . bilateral oophorectomy ) Naturally surgically sterile ( hysterectomy ; bilateral oophorectomy ; bilateral tubal ligation surgery least 6 week prior study initiation ) Of childbearing potential negative urinary serological pregnancy test use least one follow contraception method : Stable hormonal contraceptive ≥ 90 day prior Visit 1 least 7 day final injection . If &lt; 90 day prior study , additional use double barrier method 90 day reach require . Placement intrauterine device ( IUD ) intrauterine system Use barrier method contraception ( e.g. , condom occlusive cap ) spermicidal foam/gel/film/cream /suppository Use double barrier method contraception ( e.g. , male condom diaphragm , male condom cervical cap ) Patients normally active otherwise judge good health Patients must willing able attend require study visit . Patients must able follow instruction . Patients must willing able give write informed consent must provide consent . Symptoms outside grass pollen season due perennial and/or nongrass seasonal allergen , patient unable avoid offend allergen . Concurrent disease might complicate interfere investigation evaluation study medication skin prick test result , : Any ocular disorder ( allergic conjunctivitis ) include presume infectious ocular disease ( bacterial , fungal , viral , etc . ) , could interfere evaluation study medication Rhinitis medicamentosa Documented evidence acute significant chronic sinusitis , upper low respiratory tract infection within 30 day Visit 2 determine Investigator Asthma , exception mild intermittent asthma Emergency room visit admission asthma 12 month prior Visit 1 history lifethreatening asthma attack ever Presence acute subacute atopic dermatitis , chronic dermatitis , urticaria factitia , urticaria due physical/chemical influence Presence emphysema bronchiectasis Autoimmune disease , cancer , concomitant illness opinion Investigator would pose safety risk compromise interpretation study result Use oral , intramuscular , intravenous corticosteroid , potent superpotent topical corticosteroid , 30 day prior screen Visit 8 Presence tattoo skin abnormality upper arm would prevent accurate assessment local skin reaction Allergy , hypersensitivity intolerance excipients study medication Anaphylactic reaction food , insect venom , exercise , drug idiopathic anaphylaxis Immunodeficiency , include immunosuppressant therapy Recurrent idiopathic angioedema Tyrosine metabolism disorder , especially tyrosinemia alkaptonuria βblocker ( include eye drop ) , monoamine oxidase medication Unable receive epinephrine therapy ( i.e. , use epinephrine contraindicate ) Clinical history drug alcohol abuse , Investigator 's discretion , would interfere patient 's participation study Any clinically significant abnormal laboratory value ( determined Investigator ) Visit 1 Study site staff immediate relative study site staff individual would access clinical study protocol people consider vulnerable institutionalized Have undergo specific immunotherapy comparable allergen extract . An exception allow prior immunotherapy comparable allergen successful , symptom reappear sometime stop immunotherapy , immunotherapy complete ≥ 3 year Visit 1 Treatment preparation contain MPL® within 6 month prior Visit 1 . Participation clinical research study investigational medicinal product within 4 week Visit 1 concomitantly study , include safety followup period 12 month follow last injection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>